Suggested remit: To appraise the clinical and cost effectiveness of mosunetuzumab within its marketing authorisation for treating relapsed or refractory follicular lymphoma.
Status Awaiting development
Process STA 2018
ID number 3931

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
08 December 2021 - 14 January 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance